Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Essential structure of orexin 1 receptor antagonist YNT-707, Part I: Role of the 4,5-epoxy ring for binding with orexin 1 receptor.
Yamamoto N, Ohrui S, Okada T, Yata M, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ogawa Y, Ishikawa Y, Watanabe Y, Hayakawa D, Gouda H, Yanagisawa M, Nagase H. Yamamoto N, et al. Among authors: hayakawa d. Bioorg Med Chem Lett. 2017 Sep 1;27(17):4176-4179. doi: 10.1016/j.bmcl.2017.07.011. Epub 2017 Jul 4. Bioorg Med Chem Lett. 2017. PMID: 28739044
Essential structure of orexin 1 receptor antagonist YNT-707, part III: Role of the 14-hydroxy and the 3-methoxy groups in antagonistic activity toward the orexin 1 receptor in YNT-707 derivatives lacking the 4,5-epoxy ring.
Yamamoto N, Ohrui S, Okada T, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ogawa Y, Ishikawa Y, Watanabe Y, Hayakawa D, Gouda H, Yanagisawa M, Nagase H. Yamamoto N, et al. Among authors: hayakawa d. Bioorg Med Chem. 2019 Apr 15;27(8):1747-1758. doi: 10.1016/j.bmc.2019.03.010. Epub 2019 Mar 5. Bioorg Med Chem. 2019. PMID: 30871861
Essential structure of orexin 1 receptor antagonist YNT-707, Part II: Drastic effect of the 14-hydroxy group on the orexin 1 receptor antagonistic activity.
Ohrui S, Yamamoto N, Saitoh T, Kutsumura N, Nagumo Y, Irukayama-Tomobe Y, Ogawa Y, Ishikawa Y, Watanabe Y, Hayakawa D, Gouda H, Yanagisawa M, Nagase H. Ohrui S, et al. Among authors: hayakawa d. Bioorg Med Chem Lett. 2018 Feb 15;28(4):774-777. doi: 10.1016/j.bmcl.2017.12.069. Epub 2017 Dec 30. Bioorg Med Chem Lett. 2018. PMID: 29338909
Design, synthesis, and evaluation of novel inhibitors for wild-type human serine racemase.
Takahara S, Nakagawa K, Uchiyama T, Yoshida T, Matsumoto K, Kawasumi Y, Mizuguchi M, Obita T, Watanabe Y, Hayakawa D, Gouda H, Mori H, Toyooka N. Takahara S, et al. Among authors: hayakawa d. Bioorg Med Chem Lett. 2018 Feb 1;28(3):441-445. doi: 10.1016/j.bmcl.2017.12.021. Epub 2017 Dec 13. Bioorg Med Chem Lett. 2018. PMID: 29277459
In Silico Screening Identified Novel Small-molecule Antagonists of PAC1 Receptor.
Takasaki I, Watanabe A, Yokai M, Watanabe Y, Hayakawa D, Nagashima R, Fukuchi M, Okada T, Toyooka N, Miyata A, Gouda H, Kurihara T. Takasaki I, et al. Among authors: hayakawa d. J Pharmacol Exp Ther. 2018 Apr;365(1):1-8. doi: 10.1124/jpet.117.245415. Epub 2018 Jan 23. J Pharmacol Exp Ther. 2018. PMID: 29363578
165 results